RARE shares hit all-time low after failed Angelman syndrome trial
Ultragenyx Pharmaceutical (RARE) logged its worst trading day on record and closed at an all-time low Thursday after its Angelman syndrome treatment failed a key trial, triggering Wall Street target cuts and takeover speculation from Martin Shkreli.